Pacific Bio (PACB) Reports In-Line Q4 EPS, Misses on Revenue

Pacific Bio (NASDAQ: PACB) reported Q4 EPS of ($0.20), in-line with the analyst estimate of ($0.20). Revenue for the quarter came in at $39.2 million versus the consensus estimate of $40.61 million.

For earnings history and earnings-related data on Pacific Bio (PACB) click here.

You May Also Be Interested In

• Micron Technology (MU) PT Raised to $1,300 at Bernstein SocGen Group
• Kalshi in early talks for IPO - The Information
• JPMorgan Upgrades YDUQS Participacoes SA (YDUQ3:BZ) to Overweight